What is the official website of MSD GCC ?

The official website of MSD GCC is http://www.msd.com.

What is MSD GCC's cybersecurity risk score?

MSD GCC has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD GCC experienced?

According to Rankiteo, MSD GCC currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD GCC been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD GCC has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD GCC have SOC 2 Type 1 certification ?

According to Rankiteo, MSD GCC is not certified under SOC 2 Type 1.

Does MSD GCC have SOC 2 Type 2 certification ?

According to Rankiteo, MSD GCC does not hold a SOC 2 Type 2 certification.

Does MSD GCC comply with GDPR ?

According to Rankiteo, MSD GCC is not listed as GDPR compliant.

Does MSD GCC have PCI DSS certification ?

According to Rankiteo, MSD GCC does not currently maintain PCI DSS compliance.

Does MSD GCC comply with HIPAA ?

According to Rankiteo, MSD GCC is not compliant with HIPAA regulations.

Does MSD GCC have ISO 27001 certification ?

According to Rankiteo,MSD GCC is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD GCC operate in ?

MSD GCC operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD GCC have ?

MSD GCC employs approximately 103 people worldwide.

Does MSD GCC own any subsidiaries ?

MSD GCC presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD GCC have ?

MSD GCC's official LinkedIn profile has approximately 235,263 followers.

Does MSD GCC have a Crunchbase profile ?

No, MSD GCC does not have a profile on Crunchbase.

Does MSD GCC have a LinkedIn profile ?

Yes, MSD GCC maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msdgcc.

How many cybersecurity incidents has MSD GCC experienced ?

As of August 2, 2026, Rankiteo reports that MSD GCC has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD GCC have ?

MSD GCC has an estimated 5,720 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD GCC faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD GCC

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

MSD GCC Vendor Cyber Rating & Cyber Score

msd.com

Add Your Compliance Badge

We are inspired by the difference we can make in the lives of people around the world through innovative medicines, vaccines, and consumer health products we discover and produce. We focus our research on conditions that affect millions of people around the world - diseases like Alzheimer's, diabetes and cancer - while building strengths in new areas like biologic's. While we work to develop innovative therapies, we also work hard to make sure they're affordable. That's why we offer assistance and discount programs to help make our medicines accessible to those who need them. At today's MSD, we're applying our global reach and strength in scientific research to do more of what we're passionate about working to ensure a healthier future for

MSD GCC A.I CyberSecurity Scoring

Scoring History

MSD GCC

MSD GCC CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD GCC

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD GCC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD GCC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD GCC in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD GCC in 2026.

Incident Types MSD GCC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD GCC in 2026.

Incident History - MSD GCC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD GCC Subsidiaries

MSD GCC

Pharmaceutical Manufacturing

Website: http://www.msd.com

Company Size: 103

MSDPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD LATAMPharmaceutical Manufacturing

MSD Animal HealthPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD SwitzerlandPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

Loading…

MSD GCC Similar Companies

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Loading…

NEWS

MSD GCC CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Why global pharma companies choose India for GCCs

July 31, 2024 | Wednesday | Views | By Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) ...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18556

SUMMARY

Authentication bypass using an alternate path or channel vulnerability in N-able N-central allows Authentication Bypass. This issue affects N-central: through 2026.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://uptime.n-able.com/

CVE-2026-55735

SUMMARY

Improper Verification of Cryptographic Signature in ueberauth guardian allows an unauthenticated attacker to revoke a victim's session with a forged token. Guardian.revoke/3 in lib/guardian.ex decodes the supplied token with peek/1, which performs no signature verification (it only base64-decodes the JWT header and payload). The resulting unverified claims are forwarded directly to the configured token module's revoke callback and the implementation's on_revoke callback, a state-mutating sink. The sibling operations refresh/2 and exchange/4 both call decode_and_verify first, so the signature is checked before anything acts on the claims; revoke/3 is the only state-mutating path that acts on claims without verifying the signature. An attacker who knows or guesses a victim's identifying claim values (jti, sub) can forge a JWT carrying those claims, sign it with an arbitrary key, and submit it to any endpoint that funnels a caller-supplied token into Guardian.revoke/3 (the standard logout / session-revocation pattern). When the token module mutates state keyed by the claims (whitelist deletion or blacklist insertion, for example a GuardianDb-style store), the victim's legitimate session is evicted. This is an unauthenticated session-revocation denial of service; the attacker never needs the signing secret. This issue affects guardian: from 1.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55734

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in ueberauth guardian (Guardian.Permissions module) allows a denial of service via BEAM atom-table exhaustion. This vulnerability is associated with program file lib/guardian/permissions.ex and program routines 'Elixir.Guardian.Permissions':encode_permissions!/1, 'Elixir.Guardian.Permissions':encode_permissions_into_claims!/2, 'Elixir.Guardian.Permissions':do_encode_permissions!/2. The Guardian.Permissions mixin installs a public encode_permissions!/1 function on every module that does use Guardian.Permissions. For each key of the supplied map, encode_permissions!/1 calls String.to_atom(to_string(k)) before any validation runs. The integer-value clause of do_encode_permissions!/2 then short-circuits straight to encoding without validating the key against the configured permission set, so a key with an integer value is interned as a fresh atom with no exception raised. Atoms are never garbage collected and the BEAM atom table is a fixed-size resource (default roughly 1,048,576 entries), so each unique attacker-chosen key permanently consumes one slot. An attacker who can influence a permission map that reaches encode_permissions!/1 (for example a permissions map read from a request body and passed into token issuance via encode_permissions_into_claims!/2) can mint an unbounded number of atoms and exhaust the atom table, crashing the entire BEAM node and every service running on it. The sibling decode_permissions/1 is not affected because it skips keys absent from the configured permission set. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55733

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-controlled binary input. Guardian.Permissions.AtomEncoding encodes permission scopes by passing arbitrary binaries to String.to_atom/1. When encode/3 in lib/guardian/permissions/atom_encoding.ex is called with a list, each binary entry is handled by the encode_value/3 binary clause, which calls String.to_atom(value) with no allow-list check. The perm_set argument (the application's small, finite set of legitimate permission names) is discarded, so any external string flows straight into atom creation. This encoder is selected with use Guardian.Permissions, encoding: Guardian.Permissions.AtomEncoding and reached through the imported encode/3 entry point. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that funnels attacker-influenced permission scopes (from a request body, a JWT claim, or other external input) into encode/3 therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node with system_limit, taking down every application running on it. The default encoder is Guardian.Permissions.BitwiseEncoding, which is not affected. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54894

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-influenced binary input. Guardian.Plug.Keys derives connection and session namespace keys by passing arbitrary binaries to String.to_atom/1. base_key/1 in lib/guardian/plug/keys.ex converts any binary into the atom :"guardian_<input>", and the derived helpers claims_key/1, resource_key/1, and token_key/1 create a second atom on top of that. key_from_other/1 likewise converts a regex-captured binary through String.to_atom/1. The public specs advertise String.t() as a valid argument, so passing a string is documented usage, and higher-level entry points such as Guardian.Plug.current_token(conn, key: key) thread the caller-supplied key straight into these functions. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that routes attacker-influenced data (a tenant identifier, header, or other request input) into a Guardian key therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node, taking down every application running on it. This issue affects guardian: from 0.1.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…